Kenvue Inc. (NYSE:KVUE – Get Free Report) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $22.64.
A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft upped their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. UBS Group upped their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd.
View Our Latest Stock Analysis on KVUE
Institutional Inflows and Outflows
Kenvue Trading Down 1.3 %
NYSE:KVUE opened at $23.18 on Friday. The stock’s 50 day moving average price is $22.97 and its 200 day moving average price is $21.05. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market capitalization of $44.44 billion, a P/E ratio of 42.15, a P/E/G ratio of 2.20 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the company posted $0.31 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. On average, research analysts forecast that Kenvue will post 1.07 EPS for the current fiscal year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.54%. Kenvue’s payout ratio is 149.09%.
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Tesla Poised to Hit Record Highs This Holiday Season
- Stock Splits, Do They Really Impact Investors?
- The Salesforce Rally is Just Getting Started: Here’s Why
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.